Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Int J Hyperthermia. 2024;41(1):2308063. doi: 10.1080/02656736.2024.2308063. Epub 2024 Feb 5.
To evaluate the complications associated with microwave ablation (MWA) in treating persistent/recurrent hyperparathyroidism (HPT) post-surgical or ablative treatments.
From January 2015 to December 2022, 87 persistent/recurrent HPT patients (primary HPT [PHPT]: secondary HPT [SHPT] = 13:74) who underwent MWA after surgical or ablative treatment were studied. Grouping was based on ablation order (initial vs. re-MWA), prior treatment (parathyroidectomy [PTX] vs. MWA), and etiology (PHPT vs. SHPT). The study focused on documenting and comparing treatment complications and analyzing major complication risk factors.
Among the 87 patients, the overall complication rate was 17.6% (15/87), with major complications at 13.8% (12/87) and minor complications at 3.4% (3/87). Major complications included recurrent laryngeal nerve (RLN) palsy (12.6%) and Horner syndrome (1.1%), while minor complications were limited to hematoma (3.4%). Severe hypocalcemia noted in 21.6% of SHPT patients. No significant differences in major complication rates were observed between initial and re-MWA groups (10.7% vs. 13.8%, = 0.455), PTX and MWA groups (12.5% vs. 15.4%, = 0.770), or PHPT and SHPT groups (15.4% vs. 13.5%, > 0.999). Risk factors for RLN palsy included ablation of superior and large parathyroid glands (>1.7 cm). All patients recovered spontaneously except for one with permanent RLN palsy in the PTX group (2.1%).
Complication rates for MWA post-surgical or ablative treatments were comparable to initial MWA rates. Most complications were transient, indicating MWA as a viable and safe treatment option for persistent/recurrent HPT patients.
评估微波消融(MWA)治疗术后或消融治疗后持续性/复发性甲状旁腺功能亢进症(HPT)相关并发症。
本研究纳入 2015 年 1 月至 2022 年 12 月间 87 例接受过手术或消融治疗后行 MWA 的持续性/复发性 HPT 患者(原发性 HPT [PHPT]:继发性 HPT [SHPT]=13:74)。分组基于消融顺序(首次 vs. 再次 MWA)、既往治疗(甲状旁腺切除术 [PTX] vs. MWA)和病因(PHPT vs. SHPT)。研究重点记录和比较治疗并发症,并分析主要并发症的危险因素。
87 例患者中,总并发症发生率为 17.6%(15/87),其中重大并发症发生率为 13.8%(12/87),轻微并发症发生率为 3.4%(3/87)。重大并发症包括喉返神经(RLN)麻痹(12.6%)和霍纳综合征(1.1%),而轻微并发症仅限于血肿(3.4%)。21.6%的 SHPT 患者出现严重低钙血症。首次和再次 MWA 组(10.7% vs. 13.8%, = 0.455)、PTX 和 MWA 组(12.5% vs. 15.4%, = 0.770)或 PHPT 和 SHPT 组(15.4% vs. 13.5%, > 0.999)间重大并发症发生率无显著差异。RLN 麻痹的危险因素包括消融大于 1.7cm 的上极和大甲状旁腺。除了 1 例 PTX 组出现永久性 RLN 麻痹的患者外(2.1%),所有患者均自发恢复。
术后或消融治疗后 MWA 的并发症发生率与首次 MWA 相当。大多数并发症是短暂的,表明 MWA 是治疗持续性/复发性 HPT 患者的可行且安全的选择。